MARONGIU, Andrea
 Distribuzione geografica
Continente #
NA - Nord America 2.518
AS - Asia 1.739
SA - Sud America 1.010
EU - Europa 979
AF - Africa 67
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.320
Nazione #
US - Stati Uniti d'America 2.425
BR - Brasile 852
SG - Singapore 754
IT - Italia 441
CN - Cina 293
HK - Hong Kong 251
VN - Vietnam 186
DE - Germania 144
FR - Francia 91
AR - Argentina 59
GB - Regno Unito 59
FI - Finlandia 58
IN - India 38
TR - Turchia 34
CA - Canada 33
MX - Messico 33
UA - Ucraina 31
BD - Bangladesh 27
RU - Federazione Russa 26
IQ - Iraq 25
NL - Olanda 25
VE - Venezuela 23
ZA - Sudafrica 20
EC - Ecuador 19
CO - Colombia 18
PL - Polonia 18
SE - Svezia 18
KR - Corea 17
PK - Pakistan 13
UZ - Uzbekistan 13
AT - Austria 12
JP - Giappone 12
CZ - Repubblica Ceca 11
AZ - Azerbaigian 10
BE - Belgio 10
CL - Cile 10
ES - Italia 10
JM - Giamaica 10
ID - Indonesia 8
KE - Kenya 8
PY - Paraguay 8
IL - Israele 7
LT - Lituania 7
UY - Uruguay 7
BO - Bolivia 6
PE - Perù 6
TN - Tunisia 6
AU - Australia 5
DZ - Algeria 5
KZ - Kazakistan 5
MA - Marocco 5
MY - Malesia 5
SA - Arabia Saudita 5
KG - Kirghizistan 4
NP - Nepal 4
PH - Filippine 4
SN - Senegal 4
TT - Trinidad e Tobago 4
AE - Emirati Arabi Uniti 3
CR - Costa Rica 3
EG - Egitto 3
GE - Georgia 3
GH - Ghana 3
OM - Oman 3
AL - Albania 2
BG - Bulgaria 2
CH - Svizzera 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
GA - Gabon 2
GT - Guatemala 2
GY - Guiana 2
HN - Honduras 2
IR - Iran 2
JO - Giordania 2
LB - Libano 2
NO - Norvegia 2
PT - Portogallo 2
QA - Qatar 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CD - Congo 1
CG - Congo 1
CY - Cipro 1
ET - Etiopia 1
GM - Gambi 1
GR - Grecia 1
HR - Croazia 1
IM - Isola di Man 1
KW - Kuwait 1
LU - Lussemburgo 1
LV - Lettonia 1
NE - Niger 1
NG - Nigeria 1
NI - Nicaragua 1
PA - Panama 1
RO - Romania 1
Totale 6.312
Città #
Dallas 1.200
Singapore 411
San Jose 282
Hong Kong 247
Ashburn 160
Beijing 122
Chandler 78
Munich 71
Ho Chi Minh City 67
Lauterbourg 61
São Paulo 57
Cagliari 49
Los Angeles 47
Hanoi 42
New York 41
Shanghai 39
Belo Horizonte 33
Rome 33
Boardman 32
Rio de Janeiro 28
Turku 26
Helsinki 25
Milan 25
Orem 20
Sassari 19
Florence 18
West Jordan 18
Santa Clara 17
Seoul 17
Brasília 16
Buenos Aires 16
Frankfurt am Main 16
Warsaw 16
Chicago 15
Princeton 14
Johannesburg 13
Montreal 13
Nuremberg 13
Recife 13
Stockholm 13
Tashkent 13
Alghero 12
Jacksonville 12
Poplar 12
Ankara 11
Atlanta 11
Bologna 11
Boston 11
Brooklyn 11
Denver 11
Falkenstein 11
Manaus 11
Salvador 11
Baku 10
Campinas 10
Chennai 10
Düsseldorf 10
Guarulhos 10
London 10
Manchester 10
Tokyo 10
Baghdad 9
Curitiba 9
Goiânia 9
Guayaquil 9
Kingston 9
Seattle 9
Brussels 8
Council Bluffs 8
Mexico City 8
Nova Iguaçu 8
Ribeirão Preto 8
Romola 8
Santiago 8
Brno 7
Columbus 7
Istanbul 7
Lappeenranta 7
Nairobi 7
Pelotas 7
The Dalles 7
Wilmington 7
Amsterdam 6
Ann Arbor 6
Anápolis 6
Dearborn 6
Dhaka 6
Fortaleza 6
Mumbai 6
Nanjing 6
Osasco 6
Selargius 6
Shenzhen 6
Toronto 6
Trieste 6
Asunción 5
Buffalo 5
Campo Grande 5
Caxias do Sul 5
Conselheiro Lafaiete 5
Totale 3.940
Nome #
The role of 123I-MIBG cardiac scintigraphy in the patients with movement disorders (MD). 337
The impact of risk factors ascertained at the surgery of the primary tumor on metastasis appearance and outcome of patients with papillary thyroid microcarcinoma (PTMC). 325
131I-SPECT/CT in neck lymph node metastasis detection in patients with differentiated thyroid carcinomas (DTC) in long-term follow-up 183
Brain 18F-FDG PET/CT usefulness in primary progressive aphasia variant diagnosis and in their development into Alzheimer’s disease or fronto-temporal dementia 176
123I-Ioflupane brain SPECT (I-SPECT) and brain parenchyma sonography (BPS) combined use in movement disorder diagnosis 173
Cortical metabolic 18F-FDG PET assessment and striatal dopamine transporter SPECT imaging in suspected early neurodegenerative disorders with uncertain movement and cognitive symptoms 153
18F-FDG PET/CT in patients with autoimmune encephalitis in the early stage. 150
The diagnostic usefulness of131i-spect/ct at both radioiodine ablation and during long-term follow-up in patients thyroidectomized for differentiated thyroid carcinoma: Analysis of tissue risk factors ascertained at surgery and correlated with metastasis appearance 142
Qualitative (Q) and semiquantitative (SQ) brain 18FFDG PET analyses in primary progressive aphasia (PPA) variants 141
Neck lymph node metastases in patients with differentiated thyroid carcinoma (DTC) in long-term follow-up: a diagnostic 131I-SPECT/CT study 139
18F-FDG Brain PET/CT Metabolic Imaging in Patients with Suspected Autoimmune Encephalitis (AE) in the Early Stage: Can the Procedure Play a Complementary Diagnostic Role? 135
18F-FDG brain and whole body (WB) PET/CT in intracranial leptomeningeal carcinomatosis and in paraneoplastic neurologic syndromes 131
131I-SPECT/CT usefulness in patients with Hashimoto’s thyroiditis (HT) coexistence with papillary thyroid carcinoma (PC) without risk factors at surgery followed in a long-term follow-up after thyroidectomy and radioiodine ablation 130
Neck lymph node metastasis detection in patients with differentiated thyroid carcinoma (DTC) in long-term follow-up: a 131I-SPECT/CT study. 128
A multicenter 18F-FDG-PET/CT study in solitary pulmonary nodule: Qualitative and Semiquantitative parameters to predict the risk of malignancy 123
Axillary lymph node hypermetabolism (ALNH) related to COVID-19 vaccination in cancer patients undergoing 18F-FDG PET/CT: a single centre study on 500 cases 122
The prognostic role of baseline and post neoadjuvant chemotherapy [18F]FDG PET/CT in triple-negative breast cancer: preliminary results of TRINE-PET trial 122
Qualitative and semiquantitative parameters in solitary pulmonary nodule: a multicenter 18F-FDG-PET/CT study 116
Hashimoto's Thyroiditis and Papillary Thyroid Carcinoma: A Follow-Up Study in Patients with Absence of Aggressive Risk Factors at the Surgery of the Primary Tumor 116
A Comparative Follow-Up Study of Patients with Papillary Thyroid Carcinoma Associated or Not with Graves' Disease 115
Harmonization of multi-center data for preliminary investigation of cardiac MIBG scintigraphy in Parkinsonism (ITA-MIBG STUDY): a novel approach using phantom calibration with tube and bottle. 113
Large Italian Multicenter Study on Prognostic Value of Baselines Variables in mCRPC Patients Treated with 223RaCl2: Ten Years of Clinical Experience 111
Brain 123I-ioflupane SPECT and 18F-FDG PET combined use in movement and cognitive associated diseases of recent appearance 109
Differential Diagnosis of Alzheimer Disease vs. Mild Cognitive Impairment Based on Left Temporal Lateral Lobe Hypomethabolism on 18F-FDG PET/CT and Automated Classifiers 108
131I-SPECT/CT at the first radioiodine ablation and during follow-up in patients with differentiated thyroid carcinoma (DTC). 108
Breast-Specific Gamma Imaging: An Added Value in the Diagnosis of Breast Cancer, a Systematic Review 107
Performance Analysis of Six Semi-Automated Tumour Delineation Methods on [18F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in Patients with Head and Neck Cancer 103
Pet-radiomics in lymphoma and multiple myeloma: update of current literature 102
Radiomics analysis on PET/CT scans to discriminate malignant (adenocarcinoma) and benign pulmonary nodules 101
Multi-centre data harmonisation applied to heart-to-mediastinum quantification in parkinsonism (ITA-MIBG): a cross-calibration phantom study with tube and bottle 101
131I-SPECT/CT after radioiodine therapy in patients with differentiated thyroid carcinoma 101
A multicenter study for the analysis of early onset Parkinson’s disease population: the role of 123I-FP-CIT and 123I-MIBG 100
123I-MIBG Cardiac Scintigraphy and Heart/Mediastinum Ratio in Neurodegenerative Disorders: Is Delayed Scan Really Necessary? 97
Prognostic role of the risk factors in the follow-up of T1B-T2 papillary thyroid carcinoma (PC) 96
Brain SPECT DAT imaging and 18F-FDG PET/CT combined use in the early stage of movement and cognitive associated neurodegenerative disorders 96
The Role of Risk Factors for the Progression of Patients with T1b-T2 Papillary Thyroid Carcinoma (PC) during Long-Term Follow-Up 95
The DASciS Software for BSI Calculation as a Valuable Prognostic Tool in mCRPC Treated with 223RaCl2: A Multicenter Italian Study 93
Prostate-Specific Membrane Antigen Radioligand Therapy in Non-Prostate Cancers: Where Do We Stand? 91
First-, Second-, and Third-Generation Radiolabeled Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Positron Emission Tomography: State of the Art, a Systematic Review 88
Minimal Extrathyroid Extension (mETE) as the Only Risk Factor in Patients with Papillary Thyroid Carcinoma (PC): Its Clinical Impact on Recurrence and Outcome during Long-Term Follow-Up 86
Complete Blood Count-Based Biomarkers as Predictors of Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients with PD-L1 < 50% Treated with First-Line Chemoimmunotherapy 86
Utility of shape and texture features from [18F]-FDG PET to predict cervical nodal status in patients with head & neck cancer 85
18F-FDG PET/CT (PET) and serum neurodegenerative biomarkers (NB) in suspected cognitive disorders (CD): a preliminary study 84
The role of routine 131I-SPECT/CT use in differentiated thyroid carcinoma (DTC) follow-up 83
Evaluation of Bone Scan Index as a Prognostic Tool in Breast Cancer Patients with Bone Metastasis 83
The prognostic role of [18F]FDG PET/CT for suspected recurrence or monitoring systemic treatment in triplenegative breast cancer: preliminary results of the TRINE-PET trial. 82
Qualitative and Semiquantitative Parameters of 18F-FDG-PET/CT as Predictors of Malignancy in Patients with Solitary Pulmonary Nodule 80
Prognostic role of minimal extrathyroidal tumor extension (mETE) in the follow-up of patients with papillary carcinoma (PC) unaffected by other risk factors. 77
Radiomics Features from Positron Emission Tomography with [18F] Fluorodeoxyglucose Can Help Predict Cervical Nodal Status in Patients with Head and Neck Cancer 75
The prognostic role of baseline and post neoadjuvant chemotherapy [18F]FDG PET/CT in triple-negative breast cancer: preliminary results of the TRINE-PET trial 73
Usefulness of PET/CT with 18F-FDG in Patients with Differentiated Thyroid Carcinoma after Radioiodine Therapy: An Italian Multicenter Study 70
Role of Functional Neuroimaging with 123I-MIBG and 123I-FP-CIT in De Novo Parkinson's Disease: A Multicenter Study 66
Radionuclide-based nanotechnologies in brain tumors: an updated overview 60
Personalized Dosimetry in the Context of Radioiodine Therapy for Differentiated Thyroid Cancer 60
Long-term follow-up of patients thyroidectomized for thyroid papillary carcinoma (PC) with associated Graves’s disease (GD): a 131I-SPECT/CT diagnostic study 57
The impact of [18F]FDG PET/CT in guiding the change of management of triple-negative breast cancer patients: a sub-analysis of the TRINE-PET trial 35
Artificial Intelligence in PET Imaging for Alzheimer’s Disease: A Narrative Review 29
Diagnostic Accuracy of DaTQUANT® Versus BasGanV2™ for 123I-Ioflupane Brain SPECT: A Machine Learning-Based Differentiation of Parkinson’s Disease and Essential Tremor 19
Machine learning for automated differentiation of parkinson’s disease and its mimics using ¹²³I-mIBG scintigraphy: insights from a multicentre real-world cohort (ITA-mIBG study) 19
SPECT-based radiomics in oncology: current evidence, technical challenges, and future directions 17
Exploring the impact of Cabotegravir‐Rilpivirine long‐acting on weight gain, body composition and quality of life in adults living with HIV 16
Totale 6.419
Categoria #
all - tutte 21.157
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.157


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20216 0 0 0 0 0 0 0 0 0 6 0 0
2021/202243 5 2 8 0 0 2 0 3 2 2 2 17
2022/2023153 8 14 2 35 8 30 4 15 26 2 6 3
2023/2024370 42 28 9 33 94 41 0 6 1 20 26 70
2024/20252.126 44 48 121 96 79 100 106 321 664 313 124 110
2025/20263.625 179 832 610 480 393 192 517 112 147 163 0 0
Totale 6.419